JPS5931516B2 - 7-Methoxycephalosporin derivative - Google Patents

7-Methoxycephalosporin derivative

Info

Publication number
JPS5931516B2
JPS5931516B2 JP51001246A JP124676A JPS5931516B2 JP S5931516 B2 JPS5931516 B2 JP S5931516B2 JP 51001246 A JP51001246 A JP 51001246A JP 124676 A JP124676 A JP 124676A JP S5931516 B2 JPS5931516 B2 JP S5931516B2
Authority
JP
Japan
Prior art keywords
ppm
single line
hydrogen
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51001246A
Other languages
Japanese (ja)
Other versions
JPS5283862A (en
Inventor
道彦 落合
明 森本
義弘 松下
修躬 安芸
泰一 岡田
健二 川喜多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP51001246A priority Critical patent/JPS5931516B2/en
Publication of JPS5283862A publication Critical patent/JPS5283862A/en
Publication of JPS5931516B2 publication Critical patent/JPS5931516B2/en
Expired legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Description

【発明の詳細な説明】 本発明は、一般式 亡。[Detailed description of the invention] The present invention is based on the general formula Passed away.

H。。o■゜士フーI−■、。H. . o■゜shifu I-■,.

(I) 〔式中、R^2は水素原子またはハロゲン原子を、R^
3はアセトキシメチルまたは複素環チオメチル基を、R
^4は保護されていてもよいアミノ基を示す〕で表わさ
れる7−メトキシセフアロスポリン誘導体に関するもの
である。
(I) [In the formula, R^2 is a hydrogen atom or a halogen atom, R^
3 is acetoxymethyl or heterocyclic thiomethyl group, R
The present invention relates to a 7-methoxycephalosporin derivative represented by ^4 represents an optionally protected amino group.

本発明者等は研究の結果、前記一般式(I)で表わされ
る7−メトキシセフアロスポリン誘導体が広くグラム陽
性菌、陰性菌に対し高い抗菌力を示すばかりでなく、耐
性菌ないしは従来セフアロスポリン化合物が抗菌力を示
さなかつた菌種に対しても優れた抗菌力を有することを
知り本発明を完成した。
As a result of research, the present inventors have found that the 7-methoxycephalosporin derivative represented by the general formula (I) not only exhibits high antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria, but also exhibits high antibacterial activity against resistant bacteria or conventional cephalosporin compounds. The present invention was completed based on the knowledge that the bacteria had excellent antibacterial activity even against bacterial species that did not exhibit antibacterial activity.

このような7−メトキシセフアロスポリン誘導体(I)
は、たとえば一般式H″N□R^。
Such 7-methoxycephalosporin derivatives (I)
For example, the general formula H″N□R^.

(■)〔式中の記号は前記と同意義〕で表わされる7−
メトキシセフアロスポリン誘導体と、一般式〔式中、R
1は保護されたアミノ基を、他は前記と同意義〕で表わ
されるアミノチアゾール酢酸誘導体を反応させ、要すれ
ば保護基を除去することによつて製造できる。
(■) [Symbols in the formula have the same meanings as above] 7-
A methoxycephalosporin derivative and a general formula [wherein R
1 can be produced by reacting a protected amino group with an aminothiazole acetic acid derivative represented by the same definitions as above, and removing the protecting group if necessary.

本反応の原料化合物()の4位カルボキシル基はナトリ
ウム、カリウム、トリエチルアミン塩等のアルカリ金属
、有機アミン塩、あるいはβ−メチルスルホニルエチル
、トリメチルシリル、ジメチルシレニル、ベンズヒドリ
ル、β・β・β一トリクロロエチル、フエナシル、p−
メトキシベンジル、p−ニトロベンジル、メトキシメチ
ル等、緩和な条件で、酸、アルカリの作用ないしは還元
等によつて遊離のカルボキシル基に導びき得るエステル
体などが用いられる。R3中、複素環としてはたとえば
ピリジル、Nオキシドピリジル、ピリミジル、ピリダジ
ニル、N−オキシドピリダジニル、ピラゾリル、ジアゾ
リル、チアゾリル、1・2・3−チアジアゾリル、1・
2・4−チアジアゾリル、1・3・4−チアジアゾリル
、1・2・5−チアジアゾリル、1・2・3−オキサジ
アゾリル、1・2・4−オキサジアゾリル、1・3・4
−オキサジアゾリル、1・2・5−オキサジアゾリル、
1・2・3−トリアゾリル、1・2・4−トリアゾリル
、1H−テトラゾリル、2H−テトラゾリルなど、なら
びにこれらの複素環基の置換分としてはたとえばメチル
、エチル、トリフルオロメチル、プロビル、イソプロピ
ル、ブチル、イソブチル等の低級アルキル基、たとえば
メトキシ、エトキシ、プロポキシ、イソプロポキシ、ブ
トキシ等の低級アルコキシ基、たとえば塩素、臭素等の
ハロゲン原子などが置換したものなどが繁用される。他
方の原料()のR1としては、一般のペプチド化学で使
用される脱離容易なアミノ基保ゴ基、たとえばt−ブト
キシカルボニル、p−ニトロベンジルオキシカルボニル
、β・β・β一トリクロルエトキシカルボニル、ベンジ
ルオキシカルボニル、イソボルニルオキシカルボニル基
など、あるいはプロトンで保護されたアミノ基を示す。
また、R2のハロゲン原子としては、たとえばクロル、
ブロムなどが繁用される。原料化合物()の反応性誘導
体としては酸ハライド、酸無水物、混合酸無水物、活性
アミド、活性エステル等が用いられる。本反応は通常溶
媒中で有利かつ円滑に実施し得る。溶媒としては水、ア
セトン、テトラヒドロフラン、ジオキサン、アセトニト
リル、クロロホルム、ジクロロメタン、ジクロロエチレ
ン、ピリジン、ジメチルアニリン、ジメチルホルムアミ
ド、ジメチルアセトアミド、ジメチルスルホキシドなど
、またはこれらの混合物が本発明の反応を阻害しない限
り使用される。反応温度はとくに限定されないが通常冷
却下ないし室温で行なわれる。得られた7ーメトキシセ
フアロスポリ7誘導体は、必要に応じ保ゴ基を除去して
一般式(1)で表わされる7ーメトキシセフアロスポリ
ン誘導体を与える。保ゴ基の除去は、たとえばt−ブト
キシカルボニルは酸によつて、β・β・β一トリクロル
エトキシカルボニルは亜鉛と酸によつて、p−ニトロベ
ンジルオキシカルボニルは接触還元によつて行なわれる
。4位カルボキシル基のエステル残基の除去Qζたとえ
ばベンズヒドリル、p−メトキンベンジル等は酸によつ
て、β−メチルスルホニルエチルはアルカリによつて、
トリメチルシリル、ジメチルシレニルなどは水のみで、
またβ・β・β一トリクロルエチルは亜鉛と酸によつて
、p−ニトロベンジルなどは還元によつて行なわれる。
The 4-position carboxyl group of the starting material compound () for this reaction is an alkali metal such as sodium, potassium, triethylamine salt, organic amine salt, or β-methylsulfonylethyl, trimethylsilyl, dimethylsilenyl, benzhydryl, β・β・β-trichloroethyl, Fenacil, p-
Used are esters that can be converted into free carboxyl groups by the action or reduction of acids and alkalis under mild conditions, such as methoxybenzyl, p-nitrobenzyl, and methoxymethyl. Examples of the heterocycle in R3 include pyridyl, N-oxide pyridyl, pyrimidyl, pyridazinyl, N-oxide pyridazinyl, pyrazolyl, diazolyl, thiazolyl, 1,2,3-thiadiazolyl, 1,
2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4
-oxadiazolyl, 1,2,5-oxadiazolyl,
1,2,3-triazolyl, 1,2,4-triazolyl, 1H-tetrazolyl, 2H-tetrazolyl, etc., and substituents of these heterocyclic groups include, for example, methyl, ethyl, trifluoromethyl, probyl, isopropyl, butyl. , lower alkyl groups such as isobutyl, lower alkoxy groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, and those substituted with halogen atoms such as chlorine, bromine, etc. are often used. R1 of the other raw material () is an easily-removable amino group used in general peptide chemistry, such as t-butoxycarbonyl, p-nitrobenzyloxycarbonyl, β・β・β-monotrichloroethoxycarbonyl. , benzyloxycarbonyl, isobornyloxycarbonyl, etc., or a proton-protected amino group.
Further, as the halogen atom for R2, for example, chlorine,
Brom etc. are often used. As the reactive derivative of the raw material compound (), acid halides, acid anhydrides, mixed acid anhydrides, activated amides, active esters, etc. are used. This reaction can be carried out advantageously and smoothly usually in a solvent. As a solvent, water, acetone, tetrahydrofuran, dioxane, acetonitrile, chloroform, dichloromethane, dichloroethylene, pyridine, dimethylaniline, dimethylformamide, dimethylacetamide, dimethylsulfoxide, etc., or a mixture thereof, is used as long as it does not inhibit the reaction of the present invention. . The reaction temperature is not particularly limited, but it is usually carried out under cooling or at room temperature. From the obtained 7-methoxycephalosporin 7 derivative, the protective group is removed if necessary to give a 7-methoxycephalosporin derivative represented by general formula (1). Removal of the protective group is carried out, for example, by acid for t-butoxycarbonyl, by zinc and acid for β·β·β-trichloroethoxycarbonyl, and by catalytic reduction for p-nitrobenzyloxycarbonyl. Removal of ester residue at the 4-position carboxyl group Qζ For example, benzhydryl, p-methquinbenzyl, etc. are removed by acid, β-methylsulfonylethyl is removed by alkali,
Trimethylsilyl, dimethylsilenyl, etc. are only water,
Further, β, β, β-trichloroethyl is prepared using zinc and an acid, and p-nitrobenzyl and the like are prepared by reduction.

これらの保ゴ基の除去は同時に行なつてもよく、また保
ゴ基の種類、次段の反応などを考慮していずれかを先に
除去してもよい。かくして得られた7ーメトキシセフア
ロスポリン誘導体は、4位のカルボキシル基を遊離のま
まで用いてもよいが、たとえばナトリウム、カリウム等
の無毒性カチオン、アルギニン、オルニチン、リジン、
ヒスチジン等の塩基性アミノ酸、N−メチルグルカミン
、ジエタノールアミン、トリエタノールアミン、トリス
ヒドロキシメチルアミノメタンなどのポリヒドロキシア
ルキルアミン等との塩を形成させて用いてもよい。
These protective groups may be removed at the same time, or one of them may be removed first, taking into account the type of protective groups, the next reaction, and the like. The thus obtained 7-methoxycephalosporin derivative may be used with the carboxyl group at the 4-position free, but may also be used with non-toxic cations such as sodium and potassium, arginine, ornithine, lysine,
Salts may be formed with basic amino acids such as histidine, N-methylglucamine, diethanolamine, triethanolamine, polyhydroxyalkylamines such as trishydroxymethylaminomethane, and the like.

またこれらの4位のカルボキシル基をエステル化し、た
とえば血中濃度を増加させ、有効時間を延長させる効果
のある生物学的に活性なエステル誘導体に変換して用い
ることもできる。その場合に有効なエステル基としては
、たとえばメトキシメチル、エトキシメチル、イソプロ
ポキシメチル、α−メトキシエチル、α一エトキシエチ
ル等のアルコキシメチル、α−アルコキシエチル等のα
−アルコキシ−α一置換メチル基、メチルチオメチル、
エチルチオメチル、イソプロピルチオメチル等のアルキ
ルチオメチル基、またピバロイルオキシメチル、α−ア
セトキシブチル等のアシルオキシメチル基または1−ア
シルオキシ−α一置換メチル基等が用いらtる。本発明
化合物()は、次式で示される2種のトウトメリツクフ
オーム(互変異性体構造)をと5ことが考えられるが、
本明細書においてはチアノ゛−ル型で記載した。
Furthermore, these 4-position carboxyl groups can be esterified to convert into biologically active ester derivatives that have the effect of, for example, increasing blood concentration and prolonging the effective time. Effective ester groups in this case include, for example, alkoxymethyl such as methoxymethyl, ethoxymethyl, isopropoxymethyl, α-methoxyethyl, α-ethoxyethyl, α-alkoxyethyl, etc.
-alkoxy-α monosubstituted methyl group, methylthiomethyl,
Alkylthiomethyl groups such as ethylthiomethyl and isopropylthiomethyl, acyloxymethyl groups such as pivaloyloxymethyl and α-acetoxybutyl, or 1-acyloxy-α monosubstituted methyl groups are used. It is thought that the compound of the present invention () has two types of tautomeric forms (tautomer structures) shown by the following formulas.
In this specification, the cyanol type is described.

本発明の7ーメトキシセフアロスポリン誘導体(1)は
、グラム陰性菌およびグラム陽性菌に対して広く抗菌ス
ペクトラムを有し、特にグラム陰性菌の耐性エシエリヒ
ア・コリ一(EscherichiacOli)、セラ
チア・マルセツセンス(Sarratiamarces
ens)、プロテウス0ブルガリス(PrOteusv
ul?Ris)、シユードモナス3アエルギノーサ(P
eudOmOnasaerllginOSa)などの菌
に対しては既知のセフアロスポリンに優る強い抗菌力を
有するので、人および動物のこれらの細 C菌による感
染症の治療に用いられ、優れた治療効果を示す。
The 7-methoxycephalosporin derivative (1) of the present invention has a broad antibacterial spectrum against Gram-negative and Gram-positive bacteria, and is particularly resistant to Gram-negative bacteria such as Escherichia coli (Escherichia coli) and Serratia marsetuscens ( Sarratiamarces
ens), Proteus 0 vulgaris (PrOteusv
ul? Ris), Pseudomonas 3 aeruginosa (P
Since it has stronger antibacterial activity against bacteria such as C. eudOmOmOnasaerllginOSa than known cephalosporins, it is used to treat infections caused by these bacteria in humans and animals, and exhibits excellent therapeutic effects.

本発明化合物(1)は、公知セフアロスポリン剤と同様
、注射剤、カプセル剤、錠剤、顆粒剤等として、必要に
応じ生理学的に使用可能な担体または賦形剤と共に、溶
液、懸濁剤、固形剤等として投与することができる。具
体的には、たとえば7α−メトキシー7β(2−アミノ
チアゾール−4−イルアセトアミド)−3−(1−メチ
ル−1H−テトラゾール−5イルチオメチル)−3−セ
フエム一4−カルボン酸ナトリウムを、1日Kg当り約
5〜20T!79を1日3〜4回に分割して筋肉内投与
すれば、呼吸器系.尿路系感染症に特に有効である。
The compound (1) of the present invention, like known cephalosporin agents, can be prepared as an injection, capsule, tablet, granule, etc., together with a physiologically usable carrier or excipient as necessary, as a solution, suspension, or solid. It can be administered as a drug, etc. Specifically, for example, sodium 7α-methoxy7β(2-aminothiazol-4-ylacetamido)-3-(1-methyl-1H-tetrazol-5ylthiomethyl)-3-cephem-4-carboxylate is administered for one day. About 5-20T per kg! If 79 is administered intramuscularly in 3 to 4 divided doses a day, it will improve the respiratory system. Particularly effective against urinary tract infections.

実施例 1 (1) 7α−メトキシー7β−アミノセフアロスポラ
ン酸ベンズヒドリルエステル1.6387をジクロルメ
タン10m1に溶解し、氷冷下これにピリジン1.5m
11つづいて2−(β・β・β一トリクロルエトキシカ
ルボニルアミノ)チアゾール−4−イル酢酸クロリド・
塩酸塩2.707を加えて15分間撹拌する。
Example 1 (1) 1.6387 7α-methoxy7β-aminocephalosporanic acid benzhydryl ester was dissolved in 10 ml of dichloromethane, and 1.5 ml of pyridine was added to this under ice cooling.
11Continued with 2-(β・β・β-trichloroethoxycarbonylamino)thiazol-4-ylacetic acid chloride.
Add 2.707 ml of hydrochloride salt and stir for 15 minutes.

さらに室温で20分間攪拌したのち反応液を氷水にあけ
酢酸エチルで抽出する。酢酸エチル層を0.5N塩酸、
水、5%炭酸水素ナトリウム水溶液、ついで飽和食塩水
で洗浄、硫酸マグネシウムで乾燥後酢酸エチルを留去し
て油状物が得られる。これをシリカゲルクロマトグラフ
イで分離精製し、7αーメトキシー7β−〔2−(β・
β・β一トリクロルエトキシカルボニルアミノ)チアゾ
ール4−イルアセトアミド〕セフアロスポラン酸ベンズ
ヒドリルエステル1.0967を得る。(収率39.9
%)。本品は赤外吸収スペクトル(KBr)で1770
?−1にβ−ラクタムの吸収を示す。
After further stirring at room temperature for 20 minutes, the reaction solution was poured into ice water and extracted with ethyl acetate. 0.5N hydrochloric acid for the ethyl acetate layer,
After washing with water, a 5% aqueous sodium bicarbonate solution, and then saturated brine, and drying over magnesium sulfate, ethyl acetate was distilled off to obtain an oil. This was separated and purified using silica gel chromatography, and 7α-methoxy7β-[2-(β・
β·β-Trichloroethoxycarbonylamino)thiazol 4-ylacetamide]cephalosporanic acid benzhydryl ester 1.0967 is obtained. (Yield 39.9
%). This product has an infrared absorption spectrum (KBr) of 1770
? -1 shows absorption of β-lactam.

核磁気共鳴スペクトル(60Mc.重クロロホルム中)
は1.98ppmに3位アセチル基の単線、3.33p
pmに2位メチレン水素の単線、3.34ppmに7α
−メトキシ基の単線、3.74ppmにチアゾリル酢酸
部のメチレン水素の単線、4.84ppmにトリクロル
エトキシカルボニル基のメチレン水素の単線、4.90
ppmに3位メチレン水素の四重線、5.05ppmに
6位水素の単線、6.57ppmにチアゾール環5位水
素の単線、6.85ppmにベンズヒドリルのメチン水
素の単線、7.30ppmにベンズヒドリルのフエニル
水素の単線共鳴線を示す。
Nuclear magnetic resonance spectrum (60 Mc. in deuterium chloroform)
is a single line of 3-position acetyl group at 1.98ppm, 3.33p
Single line of methylene hydrogen at 2nd position at pm, 7α at 3.34ppm
- Single line of methoxy group, single line of methylene hydrogen of thiazolyl acetic acid moiety at 3.74 ppm, single line of methylene hydrogen of trichloroethoxycarbonyl group at 4.84 ppm, 4.90
3-position methylene hydrogen quartet at ppm, 6-position hydrogen single line at 5.05ppm, thiazole ring 5-position hydrogen single line at 6.57ppm, benzhydryl methine hydrogen single line at 6.85ppm, benzhydryl at 7.30ppm A single resonance line of phenyl hydrogen is shown.

2−(β・β・β一トリクロルエトキシカルボニルアミ
ノノチアゾール一4−イル酢酸クロリド・塩酸塩の製造
2−(β・β・β一トリクロルエトキシカルボニルアミ
ノ)チアゾール−4−イル酢酸6.677をジクロルメ
タン20dに懸濁し、氷冷攪拌下これに充分磨砕した五
塩化りん4,15yを加える。
Production of 2-(β・β・β-trichloroethoxycarbonylaminonothiazol-14-yl acetic acid chloride hydrochloride) 2-(β・β・β-trichloroethoxycarbonylamino)thiazol-4-yl acetic acid 6.677 Suspend the suspension in 20 d of dichloromethane, and add 4,15 y of thoroughly ground phosphorus pentachloride while stirring on ice.

懸濁していた酸は全溶し約5分後に新しい結晶が析出す
る。1時間室温で攪拌を続けたのち、析出物を沢取し、
石油エーテルで洗浄して2−(β・β・β一トリクロル
エトキシカルボニルアミノ)チアゾール−4−イル酢酸
クロリド・塩酸塩を得る。
The suspended acid completely dissolves and new crystals precipitate after about 5 minutes. After continuing stirring at room temperature for 1 hour, the precipitate was collected,
Washing with petroleum ether gives 2-(β·β·β-trichloroethoxycarbonylamino)thiazol-4-yl acetic acid chloride hydrochloride.

6.59f7(収率84.8%)。6.59f7 (yield 84.8%).

本品は融点109.7℃(分解点)を示し元素分析値は
C8H6O3N2Cl4S−HCl計算値:C24.7
3%;Hl.8l%;N7.2l% 実測値:C24.4O%;Hl.63%;N6.94% (2) 7α−メトキシー7β−〔2−(β・β・β−
トリクロルエトキシカルボニルアミノ)チアゾール−4
−イルアセトアミド〕セフアロスポラン酸ベンズヒドリ
ルエステル990ηを90%ギ酸25m1に溶解し、氷
冷攪拌下亜鉛末8607Vを加え1時間反応させる。
This product has a melting point of 109.7℃ (decomposition point), and the elemental analysis value is C8H6O3N2Cl4S-HCl calculated value: C24.7
3%; Hl. 8l%; N7.2l% Actual value: C24.4O%; Hl. 63%; N6.94% (2) 7α-Methoxy7β-[2-(β・β・β-
trichloroethoxycarbonylamino)thiazole-4
-Ylacetamide] Cephalosporanic acid benzhydryl ester 990η is dissolved in 25 ml of 90% formic acid, and 8607V of zinc powder is added with stirring under ice cooling and reacted for 1 hour.

反応物を飽和食塩水にあけ酢酸エチルで抽出する。酢酸
エチル層を水、5%炭酸水素ナトリウム水溶液、飽和食
塩水で洗浄、硫酸マグネシウムで乾燥後酢酸エチルを留
去して7α−メトキシー7β一(2−アミノチアゾール
−4−イルアセトアミド)セフアロスポラン酸ベンズヒ
ドリルエステル472ηを得る。(収率61.5%)。
本品は赤外吸収スペクトル(KBr)で1770c!n
〜1にβ−ラクタムの吸収を示す。核磁気共鳴スペクト
ル(60Mc.重クロロホルム中)で2.00ppmに
3位アセチル基の単線、3.36ppmに2位メチレン
水素の四重線、3.45ppmに7位メトキシ基の単線
、3.56ppmにチアゾリル酢酸のメチレン水素の単
線、4.90゜ppmに2位メチレン水素の四重線、5
.08ppmに6位水素の単線、6.28ppmにチア
ゾール環5位水素の単線、6.93ppmにベンズヒド
リルのメチン水素の単線、7.30ppmにベンズヒド
リルのフエニル環水素の単線共鳴線を示す。
The reaction mixture was poured into saturated brine and extracted with ethyl acetate. The ethyl acetate layer was washed with water, 5% aqueous sodium bicarbonate solution, and saturated brine, dried over magnesium sulfate, and the ethyl acetate was distilled off to give benzene 7α-methoxy-7β-(2-aminothiazol-4-ylacetamide)cephalosporanate. Hydryl ester 472η is obtained. (Yield 61.5%).
This product has an infrared absorption spectrum (KBr) of 1770c! n
~1 shows absorption of β-lactam. Nuclear magnetic resonance spectrum (60 Mc. in deuterium chloroform) shows a single line of the acetyl group at the 3-position at 2.00 ppm, a quartet of methylene hydrogen at the 2-position at 3.36 ppm, a single line of the methoxy group at the 7-position at 3.45 ppm, and a single line of the methoxy group at the 7-position at 3.56 ppm. Single line of methylene hydrogen of thiazolyl acetic acid, quartet of methylene hydrogen at 2-position at 4.90゜ppm, 5
.. A single line of hydrogen at position 6 of the thiazole ring is shown at 08 ppm, a single line of hydrogen at position 5 of the thiazole ring is shown at 6.28 ppm, a single line of methine hydrogen of benzhydryl is shown at 6.93 ppm, and a single line of resonance line of hydrogen of the phenyl ring of benzhydryl is shown at 7.30 ppm.

(3) トリフルオロ酢酸1.5m11アニソール1.
5mjからなる革合物に氷冷攪拌下7α−メトキシー7
β−(2−アミノチアゾール−4−イルアセトアミド)
セフアロスポラン酸ベンズヒドリルエステル335〜を
加えて30分間攪拌する。
(3) Trifluoroacetic acid 1.5ml 11 anisole 1.
7α-methoxy 7 was added to a leather compound consisting of 5mj under ice-cooling and stirring.
β-(2-aminothiazol-4-ylacetamide)
Cephalosporanic acid benzhydryl ester 335~ is added and stirred for 30 minutes.

反応物を乾燥エーテル50m1に注加して析出した白色
沈殿物をとり、エーテルで洗浄し粗製の7α−メトキシ
ー7β−(2−アミノチアゾール−4−イルアセトアミ
ド)セフアロスポラン酸・トリフルオロ酢酸塩(185
mg)が得られる。これを5%炭酸水素ナトリウム水溶
液に溶かしアンバーライトXAD−2(商品名)カラム
に通し水で溶出し精製して7α−メトキシー7β−(2
−アミノチアゾール−4−イルアセトアミド)セフアロ
スポラン酸ナトリウム・3水和物が得られる。131即
(収率50.8%)。
The reaction product was poured into 50 ml of dry ether, the precipitated white precipitate was collected, and washed with ether to obtain crude 7α-methoxy 7β-(2-aminothiazol-4-ylacetamido)cephalosporanic acid trifluoroacetate (185
mg) is obtained. This was dissolved in a 5% aqueous sodium bicarbonate solution, passed through an Amberlite XAD-2 (trade name) column, eluted with water, and purified.
-aminothiazol-4-ylacetamide) sodium cephalosporanate trihydrate is obtained. 131 immediately (yield 50.8%).

元素分析値 Cl6Hl7O7N4s2Na・3H20
計算値 C37.O6%:H4.47%、NlO.8O
% 実測値 C37.36%、H4.l4%、NlO.5O
% 本品の核磁気共鳴スペクトル(100Mc.重水中)は
2.26ppmに3位アセチル基の単線、3.52pp
mに2位メチレン水素の四重線、3.70ppmに7位
メトキシ基の単線、3.80ppmにチアゾリル酢酸の
メチレン水素の単線、4・95ppmに3位のメチレン
水素の四重線、5.32ppmに6位水素の単線、6.
70ppmにチアゾール環5位水素の単線共鳴線を示す
Elemental analysis value Cl6Hl7O7N4s2Na・3H20
Calculated value C37. O6%: H4.47%, NlO. 8O
% Actual value C37.36%, H4. l4%, NlO. 5O
% The nuclear magnetic resonance spectrum of this product (100 Mc. in heavy water) has a single line of the acetyl group at the 3-position at 2.26 ppm, and a single line at 3.52 ppm.
2-position methylene hydrogen quartet at m, 7-position methoxy group single line at 3.70 ppm, thiazolyl acetic acid methylene hydrogen single line at 3.80 ppm, 3-position methylene hydrogen quartet at 4.95 ppm, 5. Single line of hydrogen at position 6 at 32 ppm, 6.
A single resonance line of hydrogen at the 5-position of the thiazole ring is shown at 70 ppm.

実施例 27α−メトキシー7β一(2−アミノチアゾ
ール−4−イルアセトアミド)セフアロスポラン酸トリ
フルオロ酢酸塩431η、1−メチル−1Hテトラゾー
ル−5−チオール108η、トリエチルベンジルアンモ
ニウムプロミド24.6ηを、炭酸水素ナトリウム20
8即を含む水4m1に加えて溶かし、窒素気流中、60
℃で6時間撹拌し反応させる。
Example 27 α-Methoxy7β-(2-aminothiazol-4-ylacetamido)cephalosporanic acid trifluoroacetate 431η, 1-methyl-1H tetrazol-5-thiol 108η, triethylbenzylammonium bromide 24.6η, hydrogen carbonate sodium 20
Dissolve in 4 ml of water containing 60%
Stir and react at ℃ for 6 hours.

反応液を冷後そのままアンバーライトXAD−2(商品
名)カラムに通し、水で溶出し分離精製して7α−メト
キシー7β−(2−アミノチアゾール−4−イルアセト
アミド)−3(1−メチル−1H−テトラゾール−5−
イルチオメチル)−3−セフエム一4−カルボン酸ナト
リウム塩を得る。158η(36.8%) −元素分析値はC,6H,7O,N8SNa− H2O
計算値 C35.68; H3.55;N2O.86実
測値 C35.56;H3.36;Nl9.83赤外吸
収スペクトル(KBr錠)で1750−1にβ−ラクタ
ムの吸収を示し核磁気共鳴スペクトル(100Mc)重
水中)は3.60ppmに2位メチレン水素の四重線、
3.65ppmに7α−メトキシ基の単線、3.77p
pmにチアゾリル酢酸部のメチレン水素の単線、4.1
7ppmにテトラゾール環上メチル水素の単線、4・3
0ppmに3位メチレン水素の四重線、5.24ppm
に6位水素の単線、6.67ppmにチアゾール環5位
水素の単線共鳴線を示す。
After cooling, the reaction solution was directly passed through an Amberlite XAD-2 (trade name) column, eluted with water, and separated and purified to obtain 7α-methoxy7β-(2-aminothiazol-4-ylacetamide)-3(1-methyl- 1H-tetrazole-5-
ylthiomethyl)-3-cephem-4-carboxylic acid sodium salt is obtained. 158η (36.8%) - Elemental analysis values are C, 6H, 7O, N8SNa- H2O
Calculated value C35.68; H3.55; N2O. 86 actual value C35.56; H3.36; Nl 9.83 The infrared absorption spectrum (KBr tablet) shows absorption of β-lactam at 1750-1, and the nuclear magnetic resonance spectrum (100 Mc) in heavy water) shows 2 at 3.60 ppm. position methylene hydrogen quartet,
Single line of 7α-methoxy group at 3.65ppm, 3.77p
Single line of methylene hydrogen in thiazolyl acetic acid moiety in pm, 4.1
Single line of methyl hydrogen on the tetrazole ring at 7ppm, 4.3
3-position methylene hydrogen quartet at 0 ppm, 5.24 ppm
shows a single line of hydrogen at the 6-position, and a single-line resonance line of hydrogen at the 5-position of the thiazole ring at 6.67 ppm.

抗菌スペクトル(Mcg/11、寒天希釈法)実施例
37α−メトキシー7β一( 2 −アミノチアゾール
− 4 −イルアセトアミド)セフアロスポラン酸トリ
フルオロ酢酸塩200〜、6−メチルピリダジン一3−
チオール1−オキシド59〜を炭酸水素ナトリウム95
Tf19を含む水2m1に加えて溶かし、これにトリエ
チルベンジルアンモニウムプロミド11mf7を加え、
窒素気流中60℃で6時間撹拌し反応させる。
Antibacterial spectrum (Mcg/11, agar dilution method) Example
37α-Methoxy7β-(2-aminothiazole-4-ylacetamide)cephalosporanic acid trifluoroacetate 200~, 6-methylpyridazine-3-
Thiol 1-oxide 59 to sodium bicarbonate 95
Add and dissolve Tf19 in 2ml of water, add 11mf7 of triethylbenzylammonium bromide,
Stir and react at 60° C. for 6 hours in a nitrogen stream.

反応液を冷後アンバーライトXAD−2(商品名)カラ
ムに通し、水で溶出精製し7α−メトキシー7β−(
2 =アミノチアゾール−4−イルアセトアミド)−
3 −( 6 −メチルピリダジン一3−イルチオメチ
ル)−3−セフエム一 4 −カルボン酸1−オキシド
ナトリウム塩を得る。62〜(収率31.6%)。
After cooling, the reaction solution was passed through an Amberlite XAD-2 (trade name) column and purified by elution with water to obtain 7α-methoxy 7β-(
2 = aminothiazol-4-ylacetamide)-
3-(6-Methylpyridazin-3-ylthiomethyl)-3-cephem-4-carboxylic acid 1-oxide sodium salt is obtained. 62~ (yield 31.6%).

元素分析値はCl9Hl9O6N6s3Na・ 4.5
H20計算値 C36.36;H4.58;Nl3.3
9実測値 C36.l2;H3.96;Nl2.64赤
外吸収スペクトル(KBr錠)で1760儂−1にβ−
ラクタムの吸収を示し、核磁気共鳴スペクトル(100
Mc、重水中)は2.61ppmにピリジン環上メチル
水素の単線、3.60ppmに2位メチレン水素の四重
線、3.65ppmに7α−メトキシ水素の単線、3.
77ppmにチアゾリル酢酸部のメチレン水素の単線、
5.24ppmに6位水素の単線、6.67ppmにチ
アゾール環5位水素の単線、7.5L7.88ppmに
それぞれピリダジン環上水素の複線共鳴線を示す。
Elemental analysis value is Cl9Hl9O6N6s3Na・4.5
H20 calculated value C36.36; H4.58; Nl3.3
9 Actual measurement value C36. l2; H3.96; Nl2.64 Infrared absorption spectrum (KBr tablet) shows β-
The absorption of lactam is shown, and the nuclear magnetic resonance spectrum (100
Mc, heavy water) has a single line of methyl hydrogen on the pyridine ring at 2.61 ppm, a quartet of methylene hydrogen at the 2-position at 3.60 ppm, a single line of 7α-methoxy hydrogen at 3.65 ppm, and 3.
A single line of methylene hydrogen in the thiazolyl acetic acid moiety at 77 ppm,
A single line of hydrogen at position 6 is shown at 5.24 ppm, a single line of hydrogen at position 5 of the thiazole ring is shown at 6.67 ppm, and a double resonance line of hydrogen on the pyridazine ring is shown at 7.5L and 7.88 ppm.

実施例 4(1) 2 −(β・β・β一トリクロルエ
トキシカルボニルアミノ)− 5 −クロルチアゾール
− 4 一イル酢酸の製法2−(β・β・β一トリクロ
ルエトキシカルボニルアミノ)チアゾール−4−イル酢
酸5Vをクロロホルム7 5m1に懸濁し、水冷下(2
4℃)塩素のジクロルメタン溶液(10%W/ V)1
4.9m1を滴下する。
Example 4 (1) 2 -(β・β・β-Trichloroethoxycarbonylamino)- 5-Chlorthiazole- 4 Production method of monoyl acetic acid 2-(β・β・β-Trichloroethoxycarbonylamino)thiazole-4- Suspend 5V of ylacetic acid in 75ml of chloroform and cool with water (2
4℃) Chlorine in dichloromethane solution (10% W/V) 1
Drop 4.9 ml.

5分後に完全な溶液が得られる。A complete solution is obtained after 5 minutes.

そのまま15分間攪拌したのち反応物を5%NaHCO
3水溶液各50ゴで3回抽出する。合わせた抽出液を希
塩酸で酸性にし析出物を沢取、クロロホルムー酢酸エチ
ルから再結晶して無色結晶3.5yを得る。本品は融点
112.0℃を示し、元素分析値はC8H6O4N2C
l4S計算値 C26.lO:Hl.64;N7.6l
実測値 C25.96; Hl.8O; N7.25(
2) 2−(β・β・β一トリクロルエトキシカルボニ
ルアミノ)− 5 −クロルチアゾール− 4 −イル
酢酸クロリド塩酸塩の製法2−(β・β・βトリクロル
エトキシカルボニルアミノ)−5 −クロルチアゾール
−4−イル酢酸4.2yをジクロルメタン10m1に懸
濁し、これに五塩化りん2.38Vを加え室温で30分
間撹拌する。
After stirring for 15 minutes, the reaction mixture was diluted with 5% NaHCO.
Extract 3 times with 50 g each of 3 aqueous solutions. The combined extracts were made acidic with dilute hydrochloric acid, the precipitate was collected and recrystallized from chloroform-ethyl acetate to obtain colorless crystals 3.5y. This product has a melting point of 112.0℃, and the elemental analysis value is C8H6O4N2C.
l4S calculation value C26. lO: Hl. 64; N7.6l
Actual value C25.96; Hl. 8O; N7.25(
2) Method for producing 2-(β・β・β-trichloroethoxycarbonylamino)-5-chlorothiazole-4-ylacetic acid chloride hydrochloride 2-(β・β・β-trichloroethoxycarbonylamino)-5-chlorothiazole- 4.2y of 4-yl acetic acid was suspended in 10ml of dichloromethane, 2.38V of phosphorus pentachloride was added thereto, and the suspension was stirred at room temperature for 30 minutes.

この間原料の酸は一たん完全にとけ、ついでクロリドの
塩酸塩が析出してくる。析出物を沢取し、少量のジクロ
ルメタンで洗浄する。
During this time, the raw acid is completely dissolved, and then chloride hydrochloride is precipitated. Collect a lot of precipitate and wash with a small amount of dichloromethane.

3.38y、無色粉末。3.38y, colorless powder.

融点99.8℃、 元素分析値はC8H5O3N2Cl5S− HCI計算
値 C22.72;Hl.43;N6.62実測値 C
23.44;Hl.63:N6.77:) 7α−メト
キシー7β−アミノセフアロスポラン酸ベンズヒドリル
エステル1.638Vをジクロルメタン10m1に溶解
し、氷冷下これにピリジン1.5m1)ついで2−(β
・β・β一トリクロルエトキシカルボニルアミノ)−
5 −クロルチアゾール−4−イル酢酸クロリド塩酸塩
2.22yを加えて15分間撹拌し、ついで室温で30
分間撹拌したのち反応液を氷水にあけ酢酸エチルで抽出
する。
Melting point: 99.8°C, elemental analysis value: C8H5O3N2Cl5S-HCI calculated value: C22.72; Hl. 43; N6.62 actual measurement value C
23.44;Hl. 63:N6.77:) 1.638 V of 7α-methoxy 7β-aminocephalosporanic acid benzhydryl ester was dissolved in 10 ml of dichloromethane, and 1.5 ml of pyridine was added to this under ice-cooling.
・β・β-Trichloroethoxycarbonylamino)−
2.22y of 5-chlorothiazol-4-yl acetate chloride hydrochloride was added and stirred for 15 minutes, then stirred at room temperature for 30 minutes.
After stirring for a minute, the reaction solution was poured into ice water and extracted with ethyl acetate.

酢酸エチル層を0.5N塩酸、水、5%NaHCO3水
溶液、ついで飽和食塩水で洗浄後硫酸マグネシウムで乾
燥し酢酸エチルを留去して油状物が得られる。本品をシ
リカゲルクロマトグラフイで分離精製し7α−メトキシ
ー7β−〔2−(β・β・β一トリクロルエトキシカル
ボニルアミノ)− 5 −クロルチアゾール−4−イル
アセトアミド〕セフアロスポラン酸ベンズヒドリルエス
テルを得る。核磁気共鳴スペクトル(60Mc)重クロ
ロホルム中)は2.00ppmに強アセチル基の単線、
3.42ppmにメトキシ基の単線、4.86ppmに
トリクロルエチル基のメチレン水素の単線を示す。(4
)本品1000Tn9を90%ギ酸25m1に溶解し、
氷冷撹拌下亜鉛末860〜を加え1時間反応させる。
The ethyl acetate layer was washed with 0.5N hydrochloric acid, water, 5% NaHCO3 aqueous solution and then saturated brine, dried over magnesium sulfate, and ethyl acetate was distilled off to obtain an oil. This product is separated and purified by silica gel chromatography to obtain 7α-methoxy7β-[2-(β·β·β-trichloroethoxycarbonylamino)-5-chlorothiazol-4-ylacetamide]cephalosporanic acid benzhydryl ester. The nuclear magnetic resonance spectrum (60Mc in deuterium chloroform) shows a strong acetyl group single line at 2.00 ppm.
A single line of methoxy group is shown at 3.42 ppm, and a single line of methylene hydrogen of trichloroethyl group is shown at 4.86 ppm. (4
) Dissolve this product 1000Tn9 in 25ml of 90% formic acid,
While cooling with ice and stirring, add 860 ml of zinc powder and allow to react for 1 hour.

反応物を飽和食塩水にあけ酢酸エチルで抽出する。酢酸
エチル層を水洗、乾燥後酢酸エチルを留去して7α−メ
トキシー7β−( 2 −アミノ− 5 −クロル−チ
アゾール−4−イルアセトアミド)セフアロスポラン酸
ベンズヒドリルエステルを得る。核磁気共鳴スペクトル
(60Mc)重クロロホルム中)は2.02ppmにア
セチル基の単線、3.48ppmにメトキシ基の単線、
5.18ppmに6位水素の単線を示す。(5) トリ
フルオロ酢酸1.5m1)アニソール1.5m1の混合
物に氷冷攪拌下7α=メトキシー7β−(2−アミノ−
5 −クロルチアゾール−4−イルアセトアミド)セ
フアロスポラン酸ベンズヒドリルエステル350〜を加
えて30分間撹拌する。
The reaction mixture was poured into saturated brine and extracted with ethyl acetate. The ethyl acetate layer is washed with water, dried, and then ethyl acetate is distilled off to obtain 7α-methoxy7β-(2-amino-5-chloro-thiazol-4-ylacetamido)cephalosporanic acid benzhydryl ester. Nuclear magnetic resonance spectrum (60Mc in deuterochloroform) shows a single line of acetyl group at 2.02 ppm, a single line of methoxy group at 3.48 ppm,
A single line of hydrogen at position 6 is shown at 5.18 ppm. (5) To a mixture of 1.5 ml of trifluoroacetic acid and 1.5 ml of anisole was added 7α=methoxy7β-(2-amino-
Add 350~ of 5-chlorothiazol-4-ylacetamido)cephalosporanic acid benzhydryl ester and stir for 30 minutes.

Claims (1)

【特許請求の範囲】 1 一般式 ▲数式、化学式、表等があります▼ 〔式中、R^3はアセトキシメチルまたは複素環チオメ
チル基を、R^2は水素原子、ハロゲン原子を、R^4
は保護されていてもよいアミノ基を示す〕で表わされる
7−メトキシセファロスポリン誘導体。
[Claims] 1 General formula▲ Numerical formulas, chemical formulas, tables, etc.▼ [In the formula, R^3 is acetoxymethyl or a heterocyclic thiomethyl group, R^2 is a hydrogen atom or a halogen atom, R^4
represents an optionally protected amino group] A 7-methoxycephalosporin derivative represented by:
JP51001246A 1976-01-01 1976-01-01 7-Methoxycephalosporin derivative Expired JPS5931516B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP51001246A JPS5931516B2 (en) 1976-01-01 1976-01-01 7-Methoxycephalosporin derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51001246A JPS5931516B2 (en) 1976-01-01 1976-01-01 7-Methoxycephalosporin derivative

Publications (2)

Publication Number Publication Date
JPS5283862A JPS5283862A (en) 1977-07-13
JPS5931516B2 true JPS5931516B2 (en) 1984-08-02

Family

ID=11496082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51001246A Expired JPS5931516B2 (en) 1976-01-01 1976-01-01 7-Methoxycephalosporin derivative

Country Status (1)

Country Link
JP (1) JPS5931516B2 (en)

Also Published As

Publication number Publication date
JPS5283862A (en) 1977-07-13

Similar Documents

Publication Publication Date Title
JPS5858353B2 (en) Cefem or penam compound and its production method
US4008246A (en) Aminothiazole derivatives
EP0189287B1 (en) Novel b-lactam antibiotics
US4546176A (en) 7-Carboxymethoxyphenylacetamido-3-cephem derivatives and antibacterial preparations containing the same
JPS5857386A (en) Cephalosporin isoquinolinium betaines
US4608373A (en) Cephem compounds
GB2049675A (en) Cephalosporin derivatives
NZ203312A (en) Cephalosporin derivatives and pharmaceutical compositions
JPS6027677B2 (en) New method for producing 7-substituted or unsubstituted amino-3-substituted thiomethylcefem carboxylic acids
CA1140112A (en) Broad spectrum cephalosporin antibiotics
JPS63107989A (en) Cephalosporin compound
CA1092095A (en) 3-acyloxymethyl-cephem compounds
US4382931A (en) 3'-Substituted quinolinium cephalosporins
US4315005A (en) Cephalosporin antibiotics
JPS5910593A (en) Cephalosporin derivative
EP0142274A2 (en) Cephalosporin compounds and salts thereof, their production, and medicaments containing them
US4160830A (en) Cephalosporins
JP2529093B2 (en) Method for producing cephalosporin intermediate
JPS5931516B2 (en) 7-Methoxycephalosporin derivative
US4065619A (en) 7-(α-Sulfoacylamido)cephalosporins
US4158733A (en) 7β-Acyloxy-3-acetoxymethyl cephalosporins
JPS596879B2 (en) 7- Methoxycephalosporin
JPS60178890A (en) Novel cephalosporin derivative, and preparation thereof
US4182868A (en) 7-Methoxycephalosporin derivatives
GB2046261A (en) Cephalosporin antibiotics